Pre-Seed Round

Investment opportunity for the Go-To-Market of our Class I SaMD - TAPR.

Problem: According to the World Health Organization (WHO), approximately 50% of people in mental hospitals have a schizophrenia diagnosis, yet only 29% of individuals with psychosis receive specialist mental health care, contributing to a reduced life expectancy of 10–20 years compared to the general population.

Solution: We have developed a Class I SaMD platform that functions as a test for the mind, enabling early detection of psychosis through objective biomarkers assessment. With over 90% accuracy, it can predict the transition to psychosis up to two years before a clinical outbreak, while remaining completely language-independent.

Business Model: B2B SaaS model.